Vapogenix Inc. Unlike most pain medications that are taken orally, Vapogenix focuses on developing a new class of topical, non-opioid analgesics to alleviate pain directly at its source. By formulating volatile anesthetics for topical application, they have created an innovative solution that avoids systemic side effects.

Vapogenix's lead product, a topical analgesic, has recently completed a successful Phase II clinical trial for treating wound pain. Additionally, their second product, which has already completed its first clinical trial, is a rapidly acting topical analgesic designed to alleviate acute procedural pain, such as venipuncture and minor dermatological procedures. Furthermore, the company is developing a third topical product that targets localized inflammatory pain.

Founded by Dr. Allen Burton, Dr. Phillip Phan, and Ms.

Danguole Altman, Vapogenix was born out of their search for non-narcotic pain medications to help cancer survivors with chronic neuropathic pain. Their groundbreaking discovery that formulated volatile anesthetics can effectively alleviate localized pain serves as the foundation of the company's technology. At Vapogenix, their vision is to build a comprehensive suite of products for the treatment of various localized painful conditions.

Contact them now to learn more about their innovative approach to pain management